Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.

User seeks affordable Pyrilutamide in India for hair loss. Discusses Minoxidil, Finasteride, and RU58841 as treatments.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.

The conversation is about finding a trustworthy supplier for Pyrilutamide, a hair loss treatment. The user previously purchased RU58841 from Anagenic and is considering them for Pyrilutamide.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user experienced hair loss and itching after stopping RU58841 and resumed it to stop these symptoms. They also use Dutasteride and question which treatment is effective.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user is also interested in purchasing a high-quality red light cap for hair growth.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The conversation is about a user seeking to buy Fluridil powder or join a group buy for it. They are looking for assistance in acquiring the product.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks upcoming Fluridil group buys.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

The conclusion of the conversation is that the user "lemmeseesomeass" has experienced significant hair regrowth using a combination of RU58841, dutasteride, and minoxidil. They mention that RU58841 is effective but not medically approved. They provide instructions on how they use RU58841.

A user inquired about purchasing KX-826 for hair loss if approved in China. Another user provided links to purchase it without waiting for U.S. approval.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

A user is seeking advice on enhancing their hair loss treatment regimen, which currently includes finasteride, minoxidil, saw palmetto, and Nizoral shampoo, with plans to add oral minoxidil, a laser cap, and various supplements. They are considering purchasing additional treatments like topical finasteride, melatonin, Eucapil, and Stemoxydine from Indian and international sources.

The user experienced increased hair shedding after using RU58841 and is seeking advice on how to stop using it. They are currently using Minoxidil, Finasteride, Stemoxydine, Aminexil, Eucapil, and copper peptide serum for hair loss treatment.

A user's 12-month progress using RU58841, dutasteride, and minoxidil for hair loss. The user is open to answering questions via direct message.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

The conversation is about finding a source for RU58841 as a substitute for finasteride for hair loss treatment. Suggestions include Amazon and Anageninc.com.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.